ELI LILLY & COMPANY signed an agreement with Prasco Laboratories to market the authorized generic version of Evista (raloxifene hydrochloride tablets), in 60 mg strength in the U.S. Prasco will begin shipping the product immediately. The financial terms of the agreement were not disclosed.
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
